GC Aesthetics will proudly be participating in the 8th International Breast Symposium in Dusseldorf (IBSD) from August 27th -29th.
This event takes place with the cooperation of key associations such as the Deutsche Gesellschaft der Plastischen, Rekonstruktiven und Ästhetischen Chirurgen (DGPRÄC), the Deutsche Akademie für Senologie, the International Breast Surgery Alliance (IBSA) and more.
On Thursday, August 27th, 7 live surgeries will take place – focusing on techniques such as Prophylactic bilateral NSM and skin reducing with implant breast reconstruction and Implant exchange plus ADM/Mesh & lipofilling
Then beginning on Friday, August 28th, there will be conference sessions on topics ranging from aesthetic breast surgery, to breast reconstruction, to plastic surgery after COVID-19, and more.
On Saturday 29th, GC Aesthetics will participate in the talk “Breast Implant Technology” chaired by Günter Germann, HP van Not, which takes place at 2.55pm local time. The full program is available on the event website.
“We cordially invite plastic surgeons to the session “Breast Implant Technology” on Saturday 29th of August to learn about the latest surface innovations from GC Aesthetics which will be launched in 2020!”
During the Congress, GC Aesthetics will be showcasing HydroCone, our new sterile, single patient use device which makes inserting silicone gel implants easier.
We encourage surgeons to stop by our booth to learn about the benefits of HydroCone and how it can help them to achieve a better outcome, by optimizing their time during surgery and reducing risk of complications.
About GC Aesthetics
GC Aesthetics is an established global medical technology company that develops, manufactures in-house and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal journey.
Throughout 40 years of commercial presence, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality silicone breast implants under its premium Nagor and Eurosilicone brands, primarily for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.
The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to physicians and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.